Αρχειοθήκη ιστολογίου

Δευτέρα 5 Φεβρουαρίου 2018

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2nF6WFA

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου